2 citations
,
July 1996 in “Annals of Internal Medicine” Taking fluconazole for fungal infections might cause hair loss after about 3 months.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
January 2015 in “International journal of current research and review” The document's conclusion cannot be provided because the content is not accessible.
September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
58 citations
,
November 2000 in “Journal of the American Veterinary Medical Association” Lufenuron effectively and quickly treats fungal infections in dogs and cats without side effects.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
July 2022 in “British Journal of Dermatology”
9 citations
,
March 2024 in “Journal of Biomaterials Applications” Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
1 citations
,
July 2024 in “Clinical Case Reports” An 8-year-old with scalp fungus was successfully treated with Terbinafine, preventing hair loss and spread.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
6 citations
,
May 2012 in “The Journal of Dermatology” Fexofenadine may help treat a difficult type of hair loss.
January 2023 in “Brazilian Journals Editora eBooks” Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
20 citations
,
August 2008 in “Journal of Medical Case Reports” Ondansetron can cause serious allergic reactions, so use it carefully.
January 2012 in “The Year book of dermatology” Finasteride 5mg/day improves hair loss in normoandrogenic Asian women.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
August 2025 in “Frontiers in Pharmacology” [6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.